ATS 2020 Advance Program

The goal of the core is to support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements. The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key topics in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to help clinicians stay up to date with important information relevant to their medical practices, and to provide an opportunity for clinicians to evaluate their individual knowledge and skills while earning MOC Medical Knowledge points. Chairing: C.E. Caplan-Shaw, MD, New York, NY J.L. Cho, MD, Iowa City, IA 2:15 Community Acquired Pneumonia: Updates in Diagnosis and Management K.L. Bailey, MD, ATSF, Omaha, NE 2:45 Influenza and Respiratory Viruses in 2020 R. Alalawi, MD, Phoenix, AZ 3:15 Approach to the Diagnosis of Opportunistic Infections in Immunocompromised Patients E.M. Carmona Porquera, MD, PhD, Rochester, MN 3:45 Nontuberculous Mycobacterial Infection: MAC and Beyond C. Swenson, MD, Atlanta, GA CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE C82 PHENOTYPING ACUTE EXACERBATIONS OF COPD Assemblies on Clinical Problems; Pulmonary Infections and Tuberculosis; Respiratory Structure and Function 2:15 p.m. - 4:15 p.m. Target Audience Pulmonologists, primary care physicians, nurse practitioners, nurses and respiratory therapists with clinical and research interests in the diagnosis and treatment of exacerbations of COPD. Objectives At the conclusion of this session, the participant will be able to: • learn current and alternate definitions of acute exacerbations, and estimate exacerbation severity and its importance in patient care; • appreciate etiology and clinical course based endotyping and phenotyping of exacerbations; • gain new knowledge of biomarkers and therapies of exacerbations. The majority of COPD-related morbidity, mortality and health care costs are due to acute exacerbations, particularly those that require hospitalization. Although significant advances have been made in phenotyping and treating stable COPD, the management of acute exacerbation has not changed significantly in several decades. Recent data indicates there is considerable heterogeneity in exacerbations also, and that there is a need to identify separate endo-phenotypes. Speakers will discuss current and alternative definitions of acute exacerbations, the clinical relevance of exacerbation severity, phenotypes and endotypes of exacerbations, underappreciated causes of exacerbations, biomarkers and the therapy of exacerbations. Chairing: S.P. Bhatt, MD, MSPH, Birmingham, AL J.A. Wedzicha, MD, PhD, ATSF, London, United Kingdom J.M. Bon, MD, MS, ATSF, Pittsburgh, PA 2:15 A Patient's Perspective Speaker To Be Announced 2:20 Definition of Acute Exacerbations: Are We There Yet? A. Agusti, MD, Barcelona, Spain 2:35 “Mild” Exacerbations: Do They Matter? G.C. Donaldson, PhD, BSc(Hons), ATSF, London, United Kingdom 2:50 Clinical Phenotypes of Exacerbations J.A. Wedzicha, MD, PhD, ATSF, London, United Kingdom 3:05 Molecular Phenotyping of Exacerbations Using Genomic Approaches S. Christenson, MD, MS, San Francisco, CA ATS 2020 • Philadelphia, PA 114 TUESDAY • MAY 19